Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EPHX2 | P34913 | 4/20 | 0.48 |
| ▸ | GRIN2D | O15399 | 4/20 | 0.48 |
| ▸ | GRIN3B | O60391 | 4/20 | 0.48 |
| ▸ | GRIN1 | Q05586 | 4/20 | 0.48 |
| ▸ | GRIN2A | Q12879 | 4/20 | 0.48 |
| ▸ | GRIN2B | Q13224 | 4/20 | 0.48 |
| ▸ | GRIN2C | Q14957 | 4/20 | 0.48 |
| ▸ | GRIN3A | Q8TCU5 | 4/20 | 0.48 |
| ▸ | MEN1 | O00255 | 3/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.45 |
| ▸ | TSHR | P16473 | 1/20 | 0.45 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.41 |
| ▸ | BPTF | Q12830 | 1/20 | 0.41 |
| ▸ | CCR6 | P51684 | 1/20 | 0.41 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.41 |
| ▸ | MAPT | P10636 | 1/20 | 0.41 |
| ▸ | ATM | Q13315 | 1/20 | 0.41 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3785168 | 0.92 | EPHX2 (0.43) | EPHX2GRIN2DGRIN3BGRIN1GRIN2A | |
| SCHEMBL24728074 | 0.87 | GRIN2D (0.52) | EPHX2GRIN2DGRIN3BGRIN1GRIN2A | |
| SCHEMBL7337692 | 0.84 | EPHX2 (0.50) | EPHX2GRIN2DGRIN3BGRIN1GRIN2A | |
| SCHEMBL1323193 | 0.82 | EPHX2 (0.48) | EPHX2GRIN2DGRIN3BGRIN1GRIN2A | |
| SCHEMBL6858927 | 0.82 | EPHX2 (0.48) | EPHX2GRIN2DGRIN3BGRIN1GRIN2A | |
| SCHEMBL660423 | 0.80 | ALDH1A1 (0.53) | EPHX2GRIN2DGRIN3BGRIN1GRIN2A | |
| SCHEMBL13780945 | 0.80 | MEN1 (0.49) | EPHX2GRIN2DGRIN3BGRIN1GRIN2A | |
| SCHEMBL23791655 | 0.78 | EPHX2 (0.46) | EPHX2GRIN2DGRIN3BGRIN1GRIN2A | |
| SCHEMBL2409327 | 0.77 | EPHX2 (0.44) | EPHX2GRIN2DGRIN3BGRIN1GRIN2A | |
| SCHEMBL1074062 | 0.76 | ALDH1A1 (0.57) | EPHX2KMT2AALDH1A1TSHRBPTF |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 29 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4281081-A1 | ADENOSINE DERIVATIVE AND PHARMACEUTICAL COMPOSITION COMPRISING THE SAME | Brii Biosciences, Inc. (US) | 2023-11-29 | — | — | EP | disclosed |
| US-11793827-B2 | Adenosine derivative and pharmaceutical composition comprising the same | BRII BIOSCIENCES, INC. (US) | 2023-10-24 | — | — | US | disclosed |
| US-11793827-B2 | Adenosine derivative and pharmaceutical composition comprising the same | BRII BIOSCIENCES, INC. (US) | 2023-10-24 | — | — | US | disclosed |
| CN-116710465-A | Adenosine derivatives and pharmaceutical compositions containing the same | 腾盛博药生物科技有限公司 | 2023-09-05 | — | — | CN | disclosed |
| US-20220233567-A1 | ADENOSINE DERIVATIVE AND PHARMACEUTICAL COMPOSITION COMPRISING THE SAME | BRII BIOSCIENCES, INC. | 2022-07-28 | — | — | US | disclosed |
| WO-2022159872-A1 | ADENOSINE DERIVATIVE AND PHARMACEUTICAL COMPOSITION COMPRISING THE SAME | BRII BIOSCIENCES, INC. (US) | 2022-07-28 | — | — | WO | disclosed |
| US-8962639-B2 | Potassium channel modulators | ABBVIE INC. (US) | 2015-02-24 | — | — | US | disclosed |
| US-20100305109-A1 | POTASSIUM CHANNEL MODULATORS | ABBOTT LABORATORIES (US) | 2010-12-02 | — | — | US | disclosed |
| US-20090176853-A1 | Adamantane derivatives | ALCARAZ LILIAN | 2009-07-09 | — | — | US | disclosed |
| US-20080139636-A1 | Adamantane derivatives | ASTRAZENECA AB. | 2008-06-12 | — | — | US | disclosed |
| US-7132457-B2 | Adamantane derivatives | ASTRAZENECA AB (SE) | 2006-11-07 | — | — | US | disclosed |
| WO-2006110516-A1 | ACYLHYDRAZIDE P2X7 ANTAGONISTS AND USES THEREOF | ABBOTT LABORATORIES (US) | 2006-10-19 | — | — | WO | disclosed |
| US-20050049303-A1 | 2-Chloro-5-[3-[(2-hydroxyethyl)amino]propyl]-N-(tricyclo[3.3.1.13,7]dec-1-ylmethyl)-benzamide; preparation from chemical intermediates; use in treating rheumatoid arthritis, chronic obstructive pulmonary disease | ASTRAZENECA AB | 2005-03-03 | — | — | US | disclosed |
| EP-1242364-B1 | ADAMANTANE DERIVATIVES | ASTRAZENECA AB (SE) | 2004-03-17 | — | — | EP | disclosed |
| EP-1352895-A2 | Adamantane derivatives for the treatment of inflammatory, immune and cardiovascular diseases | AstraZeneca AB (SE) | 2003-10-15 | — | — | EP | disclosed |
| EP-1352896-A2 | Adamantane derivatives for the treatment of inflammatory, immune and cardiovascular diseases | AstraZeneca AB (SE) | 2003-10-15 | — | — | EP | disclosed |
| EP-1352897-A2 | Adamantane derivatives for the treatment of inflammatory, immune and cardiovascular diseases | AstraZeneca AB (SE) | 2003-10-15 | — | — | EP | disclosed |
| CN-1434794-A | Adamantane derivatives | ASTRAZENECA AB (SE) | 2003-08-06 | — | — | CN | disclosed |
| EP-1242364-A1 | ADAMANTANE DERIVATIVES | AstraZeneca AB (SE) | 2002-09-25 | — | — | EP | disclosed |
| WO-2001044170-A1 | ADAMANTANE DERIVATIVES | ASTRAZENECA AB (SE) | 2001-06-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11793827-B2 | Adenosine derivative and pharmaceutical composition comprising the same | ADAR, ADA, ADORA2A | EPHX2 2007/4885GRIN2D 4306/4885GRIN3B 2993/4885 |
| US-20090176853-A1 | Adamantane derivatives | ADAM33, ADAM17, BACE1 | EPHX2 138/4885GRIN2D 665/4885GRIN3B 527/4885 |
| US-20050049303-A1 | 2-Chloro-5-[3-[(2-hydroxyethyl)amino]propyl]-N-(tricyclo[3.3.1.13,7]dec-1-ylmethyl)-benzamide; preparation from chemical intermediates; use in treating rheumatoid arthritis, chronic obstructive pulmonary disease | HRH1, HRH2, HRH4 | EPHX2 248/4885GRIN2D 706/4885GRIN3B 1027/4885 |
| US-20100305109-A1 | POTASSIUM CHANNEL MODULATORS | KCNQ1, KCNQ2, KCNJ2 | EPHX2 3121/4885GRIN2D 367/4885GRIN3B 235/4885 |
| US-20220233567-A1 | ADENOSINE DERIVATIVE AND PHARMACEUTICAL COMPOSITION COMPRISING THE SAME | ADAR, ADA, ADORA2A | EPHX2 2007/4885GRIN2D 4306/4885GRIN3B 2993/4885 |
| US-20080139636-A1 | Adamantane derivatives | ADAM33, ADAM17, BACE1 | EPHX2 138/4885GRIN2D 665/4885GRIN3B 527/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.